Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on May 12, 2026. The report details the publication of a peer-reviewed manuscript on May 13, 2026, regarding the Company's investigational oral drug candidate, SKNY-1, which is being evaluated for obesity and nicotine addiction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific developments and does not contain financial statements or operational financial data.
Material Changes and Scientific Findings
The primary material event is the publication of preclinical research in the International Journal of Molecular Sciences. Key findings regarding SKNY-1 in an MC4R-deficient zebrafish model include:
- Weight Loss: Dose-dependent reductions in body weight, with approximately a 30% reduction relative to baseline in the higher-dose group after six days of treatment.
- Lipid Profile: Normalization of total cholesterol and LDL levels, increased HDL levels, and reduced hepatic triglyceride accumulation.
- Behavioral Effects: Attenuation of compulsive feeding and nicotine-seeking behaviors, as well as anxiety-like behaviors.
- Mechanism of Action: Differential engagement of CB1 signaling, partial agonist activity at CB2, and selective inhibition of MAO-B relative to MAO-A.
- Body Density: No significant reduction in whole-body density was observed during the treatment period.
Outlook, Risks, and Contingencies
Regulatory Status: SKNY-1 has not been approved by the U.S. Food and Drug Administration (FDA) for any indication. The safety and efficacy of SKNY-1 have not been established in humans.
Risk Factors: The findings are based solely on preclinical research conducted in zebrafish models and in vitro systems. There is no guarantee that these results will translate to human clinical trials.
Management Commentary: The Company highlights the differentiated CB1 pathway engagement of SKNY-1 as a key differentiator from other cannabinoid-related compounds.
Investor Verification Checklist
- Verify the full text of the manuscript at the provided MDPI link to confirm the specific dosing and methodology.
- Confirm the current cash position and runway of the Company, as this filing contains no financial data.
- Review the Company's clinical trial pipeline to determine the timeline for transitioning SKNY-1 from preclinical zebrafish models to human studies.
- Assess the competitive landscape for THCV analogs in the obesity and addiction treatment sectors.